Improving heart failure outcomes with sodium-glucose cotransporter 2 inhibitors in different patient groups.

13 In 6609 patients with an eGFR of 20‐45 ml/min/1.73 m 2 or eGFR of 45‐90 ml/min/1.73 m 2 and a urinary albumin‐to‐creatinine ratio of ≥200, empagliflozin reduced the risk of progression of kidney disease or death from CV causes but the reduction in the composite of CV death or HF hospitalization did not reach statistical significance [HR 0.84 (95% CI 0.67‐1.07)].

also in 111,027 other papers